Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.
To view more of our resources on hematologic malignancies: [ Ссылка ]
Ещё видео!
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.
To view more of our resources on hematologic malignancies: [ Ссылка ]